SEC Form 4Coverage since Jun 29, 2026
$RGNX insider trading
Over the last 12 months, REGENXBIO insiders reported no purchases and 2 sales totaling $718K across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $718K 2 events
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $RGNX · 12Mvia TradingView
Top insiders · 12m
PAKOLA STEVEChief Medical Officer2× · $718K
All insider trades
2 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | PAKOLA STEVEChief Medical Officer · O | ▼ Sale | 2,161 | $13.64 | $29K | -1% | plan |
| Jul 1, 2026 | PAKOLA STEVEChief Medical Officer · O | ▼ Sale | 56,333 | $12.23 | $689K | -20.9% | plan · 2 tranches |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RGNX feed.